The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -20,643,455 |
| Depreciation | 1,012 |
| Issuance of common stock for services | 10,716,692 |
| Options vested for stock-based compensation | 1,168,280 |
| Amortization of intangible assets | 1,122,639 |
| Amortization of license agreement | 600,552 |
| Operating lease right of use asset | 68,539 |
| Loss from settlement | -125,624 |
| Loss from debt extinguishment related parties | -19,388 |
| Due from related party-Related Party | 20,056 |
| Impairment of license agreement-Related Party | -1,239,942 |
| Prepaid expenses-Related Party | 120 |
| Prepaid expenses-Nonrelated Party | 7,021 |
| Deposits | -16,957 |
| Accounts payable and accrued liabilities | 55,669 |
| Operating lease right-of-use liabilities | -74,046 |
| Payroll tax liabilities | 9,421 |
| Other liabilities | -216,358 |
| Net cash used in operating activities | -5,850,255 |
| Proceeds from borrowings on notes payable | 500,000 |
| Proceeds from borrowings on notes payable - related parties | 175,000 |
| Proceeds from sales of common stock | 4,625,355 |
| Proceeds from sales of series b convertible preferred stock | 100,000 |
| Proceeds from exercise of warrants | 927,000 |
| Collection of subscriptions receivable | 1,150,000 |
| Repayment of borrowings on notes payable - related parties | 206,500 |
| Net cash provided by financing activities | 7,270,855 |
| End of period | 1,420,600 |
| Beginning of period | 58,653 |
| Effects of currency translation on cash and cash equivalents | 7,085 |
| End of period | 1,486,338 |
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)